Do lipid-lowering agents provide a greater reduction in cardiovascular events among patients with diabetes?
Gollapudi, A.K.
Annals of Internal Medicine 149(11): 841; Author Reply 841-2
2008
ISSN/ISBN: 0003-4819 PMID: 19047040 Document Number: 615737
Document emailed within 1 workday
Related Documents
Chen, Y.; Wang, J.; An, Y.; Gong, Q.; He, Y.; Zhang, B.; Li, H.; Shuai, Y.; Tang, X.; Jiang, Y.; Hong, J.; Yang, W.; Hu, Y.; Li, G. 2015: Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre-diabetic patients:long-term follow-up of Da Qing Diabetes Prevention Study Zhonghua Nei Ke Za Zhi 54(1): 13-17Kokot, F.; Szczechowska, E. 1981: Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 36(13): 454-457
Hartley, H. 1996: The reduction of cardiovascular events after a myocardial infarct in patients with normal cholesterol levels Revista Clinica Espanola 196(4 Monografico): 43-46
Dunn, N. 2001: Cardiovascular events in users of sildenafil. Paper does not provide any reassurance Bmj 323(7303): 50-51
1997: What is new? Therapy with lipid lowering agents Der Internist 38(11 Suppl Therapie): 1-8
Heinzl, S. 2003: Lipid and blood pressure reduction for reduction of cardiovascular mortality Medizinische Monatsschrift für Pharmazeuten 26(6): 185
Klomp, C.M.C.; ten Cate, H.; Stehouwer, C.D.A.; Schaper, N.C. 2009: Acetylsalicylic acid in patients with diabetes mellitus: can be used for secondary but not primary prevention of cardiovascular events Nederlands Tijdschrift Voor Geneeskunde 153: A109
Amarenco, P. 2001: Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction Neurology 57(5 Suppl 2): S35-S44
Wirebaugh, S.R.; Shapiro, M.L.; McIntyre, T.H.; Whitney, E.J. 1992: A retrospective review of the use of lipid-lowering agents in combination, specifically, gemfibrozil and lovastatin PharmacoTherapy 12(6): 445-450
Kuemmerle, H.P. 1981: Lipid-lowering agents and their meaning in the treatment of the fat metabolism-atherosclerosis functional circle International Journal of Clinical Pharmacology Therapy and Toxicology 19(7): 289-296
Knatterud, G.L.; Klimt, C.R.; Levin, M.E.; Jacobson, M.E.; Goldner, M.G. 1978: Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. Mortality and selected nonfatal events with insulin treatment JAMA 240(1): 37-42
Gronowitz, S.; Herslöf, M.; Svenson, R.; Bondesson, G.; Magnusson, O.; Stjernström, N.E. 1978: Potential hypolipidemic agents. XVIII. Synthesis and lipid-lowering properties of 2-(dibenzothiophenoxy)-2-methylpropionates and related compounds Acta Pharmaceutica Suecica 15(5): 337-360
Bondesson, G.; Hedbom, C.; Magnusson, O.; Stjernström, N.E. 1976: Potential hypolipidemic agents. XIII. Synthesis and plasma lipid-lowering properties of some acetals derived from 3-pyridylmethanol or nicotinaldehyde Acta Pharmaceutica Suecica 13(1): 1-8
Pearson, T.A.; Laurora, I.; Chu, H.; Kafonek, S. 2000: The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals Archives of Internal Medicine 160(4): 459-467
Miranda, V.P.; Rodrigues, M.J.O.; Gonçalves, F.R.; Nunes, J.é P.L. 2009: Effects of hypoglycemic agents on mortality and major cardiovascular outcomes in patients with type 2 diabetes mellitus: a narrative review [88 Revista Portuguesa de Cardiologia: Orgao Oficial da Sociedade Portuguesa de Cardiologia 28(10): 1099-1119
Auer, J.; Berent, R.; Weber, T.; Porodko, M.; Mayr, H.; Maurer, E.; Eber, B. 2001: Pharmacologic interventions in primary prevention: lipid lowering drugs, aspirin, antiobesity drugs, and antihypertensive agents Wiener Medizinische Wochenschrift 151(1-2): 13-17
Wagner, M.; Goetghebeur, M.; Merikle, E.; Pandya, A.; Chu, P.; Taylor, D.C.A. 2009: Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada Canadian Journal of Clinical Pharmacology 16(2): E331-E345
Krawczuk-Rybak, M.; Wójtowicz, J.; Urban, M. 1992: Lipid metabolism in patients with insulin dependent diabetes. IV. Effect of sex, age, excess body weight, duration of diabetes, insulin dosage and family history on lipid metabolism in patients with insulin dependent diabetes Endokrynologia Polska 43(2): 125-135
Lawless, C.; Force, R. 1997: Lipid lowering in post-Mi patients with normal cholesterol Journal of Family Practice 44(1): 30
Miskić, B.; Bistrović, D.; Cosić, V.; Leko, N.; Balen-Jandrić, M.; Balen, I.; Samardzić, P.; Miskić, D. 2003: Effect of raloxifene on lowering lipid parameters in patients with osteoporosis International Journal of Clinical Pharmacology Research 23(4): 107-110